# OnCo record nct06614751 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06614751/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06614751", "NCT06614751" ;
  schema:name "A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway"@en ;
  schema:description "A phase 1 trial of DAT-2645 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06614751/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06614751> ;
  onco:status "planned" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/gastric/> ;
  onco:drugs <https://onco.cc/drugs/dat-2645/> ;
  onco:companies <https://onco.cc/companies/danatlas-pharmaceuticals/> .